ATTORNEY'S DOCKET NO: C0875/7017GECL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Carlo Brugnara, et al.

Serial No: Filed:

09/942,258 August 28, 2001

For:

USE OF TRIARYL METHANE COMPOUNDS FOR INHIBITING UNWANTED

CELLULAR PROLIFERATION ASSOCIATED WITH INFLAMMATORY DISEASE

Examiner:

E. Sackey

Art Unit:

1626

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with firstclass postage attached, addressed to the Commissioner for Patents, Washington, D.C. 20231, on the 5th day of September, 2002.

Konstantinos Andrikapoulas

Konstantinos Andrikopoulos, Reg. No. 48,915

COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

Sir:

## AMENDMENT/RESPONSE TO RESTRICTION REQUIREMENT

This is in response to the Restriction Requirement mailed from the United States Patent and Trademark Office on June 5, 2002. A Petition for a Two-Month Extension of Time (on Transmittal) and appropriate fee are submitted concurrently herewith.

Please amend the above-identified application as follows:

## In the claims:

In response to the Restriction Requirement (Paper No. 6) issued June 5, 2002, please amend claims 1 and 6 as follows:

01

A method for inhibiting unwanted cellular proliferation associated with an 1. (Twice Amended) inflammatory disease, said method comprising the step of contacting a cell the proliferation of which contributes to inflammation in situ with an effective amount of